QCM
EGRX

Quantinno Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Quantinno Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-5,308
Closed -$296K – 544
2019
Q2 		$296K Sell
5,308
-4,805
-48% -$251K 0.17% 294
2019
Q1 		$511K Buy
+10,113
New +$450K 0.33% 104

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Quantinno Capital Management's EGRX Position: Q3 2019 in Review

Quantinno Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2019, closing a stake of 5,308 shares — an estimated $296K sold.

Quantinno Capital Management first reported a position in EGRX in Q1 2019 and held it in 2 quarters. The position peaked at $511K in Q1 2019. 183 funds tracked by Wall St. Rank hold EGRX as of Q3 2019.

  • Quantinno Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Quantinno Capital Management sold 5,308 Eagle Pharmaceuticals, Inc. shares in Q3 2019, an estimated $296K.
  • Quantinno Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2019 and held it in 2 quarters.
  • Quantinno Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $511K in Q1 2019.
  • 183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2019.

Based on Quantinno Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.